C4d deposition in early renal allograft protocol biopsies

被引:44
作者
Koo, DDH
Roberts, ISD
Quiroga, I
Procter, J
Barnardo, MCNM
Sutton, M
Cerundolo, L
Davies, DR
Friend, PJ
Morris, PJ
Fuggle, SV [1 ]
机构
[1] Churchill Hosp, Oxford Transplant Ctr, Oxford OX3 7LJ, England
[2] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Surg, Oxford OX3 9DU, England
[3] John Radcliffe Hosp, Dept Cellular Pathol, Oxford OX3 9DU, England
关键词
renal transplantation; C4d; acute rejection;
D O I
10.1097/01.TP.0000128328.68106.54
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Deposition of the complement protein C4d in renal allograft biopsies obtained during graft dysfunction and rejection has been proposed to be a sensitive marker of antibody-mediated acute rejection. To determine the diagnostic specificity of C4d deposition, it is important to study biopsies from allografts with no evidence of dysfunction. In this study, we examined C4d deposition in protocol biopsies obtained irrespective of clinical status. Methods. Immunohistochemistry for C4d was performed on routine protocol biopsies preimplantation and on day 7 posttransplantation from 48 unselected renal allografts. Serum samples obtained up to 1 month after transplantation were assayed for donor-reactive antibodies (DRA). Results were correlated with histopathology and clinical outcome measures. Results. Diffuse C4d deposition was detected in the peritubular capillaries of 6 of 48 (13%) biopsies. C4d deposition was present in 5 of 15 (33%) biopsies that showed acute rejection (Banff 97, category 4) but only in 1 of 33 (3%) biopsies with no rejection (P=0.003, 97% specificity). Posttransplant DRAs were detected in 21 of 48 (44%) patients. All five recipients with C4d deposition and rejection had posttransplant DRA; the recipient whose biopsy showed C4d positivity, but not rejection, did not have detectable DRA. C4d deposition was not treated with plasmapheresis or intravenous immunoglobulin and was not associated with poor posttransplant graft outcome at 1-year follow-up. Conclusions. Our results show that in early posttransplant protocol biopsies, C4d is a specific marker for the presence of humoral rejection, as indicated by its association with DRA and acute histologic rejection.
引用
收藏
页码:398 / 403
页数:6
相关论文
共 28 条
[21]   Antibody-mediated rejection criteria - an addition to the Banff '97 Classification of Renal Allograft Rejection [J].
Racusen, LC ;
Colvin, RB ;
Solez, K ;
Mihatsch, MJ ;
Halloran, PF ;
Campbell, PM ;
Cecka, MJ ;
Cosyns, JP ;
Demetris, AJ ;
Fishbein, MC ;
Fogo, A ;
Furness, P ;
Gibson, IW ;
Glotz, D ;
Hayry, P ;
Hunsickern, LN ;
Kashgarian, M ;
Kerman, R ;
Magil, AJ ;
Montgomery, R ;
Morozumi, K ;
Nickeleit, V ;
Randhawa, P ;
Regele, H ;
Seron, D ;
Seshan, S ;
Sund, S ;
Trpkov, K .
AMERICAN JOURNAL OF TRANSPLANTATION, 2003, 3 (06) :708-714
[22]   The Banff 97 working classification of renal allograft pathology [J].
Racusen, LC ;
Solez, K ;
Colvin, RB ;
Bonsib, SM ;
Castro, MC ;
Cavallo, T ;
Croker, BP ;
Demetris, AJ ;
Drachenberg, CB ;
Fogo, AB ;
Furness, P ;
Gaber, LW ;
Gibson, IW ;
Glotz, D ;
Goldberg, JC ;
Grande, J ;
Halloran, PF ;
Hansen, HE ;
Hartley, B ;
Hayry, PJ ;
Hill, CM ;
Hoffman, EO ;
Hunsicker, LG ;
Lindblad, AS ;
Marcussen, N ;
Mihatsch, MJ ;
Nadasdy, T ;
Nickerson, P ;
Olsen, TS ;
Papadimitriou, JC ;
Randhawa, PS ;
Rayner, DC ;
Roberts, I ;
Rose, S ;
Rush, D ;
Salinas-Madrigal, L ;
Salomon, DR ;
Sund, S ;
Taskinen, E ;
Trpkov, K ;
Yamaguchi, Y .
KIDNEY INTERNATIONAL, 1999, 55 (02) :713-723
[23]   Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries:: A contribution of humoral immunity to chronic allograft rejection [J].
Regele, H ;
Böhmig, GA ;
Habicht, A ;
Gollowitzer, D ;
Schillinger, M ;
Rockenschaub, S ;
Watschinger, B ;
Kerjaschki, D ;
Exner, M .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 (09) :2371-2380
[24]   Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection [J].
Regele, H ;
Exner, M ;
Watschinger, B ;
Wenter, C ;
Wahrmann, M ;
Österreicher, C ;
Säemann, MD ;
Mersich, N ;
Hörl, WH ;
Zlabinger, GJ ;
Böhmig, GA .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (10) :2058-2066
[25]   Mycophenolate mofetil decreases antibody production after cardiac transplantation [J].
Rose, ML ;
Smith, J ;
Dureau, G ;
Keogh, A ;
Kobashigowa, J .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2002, 21 (02) :282-285
[26]   Complement activation in early protocol kidney graft biopsies after living-donor transplantation [J].
Sund, S ;
Hovig, T ;
Reisaeter, AV ;
Scott, H ;
Bentdal, O ;
Mollnes, TE .
TRANSPLANTATION, 2003, 75 (08) :1204-1213
[27]   THE FLOW CYTOMETRIC DETECTION OF ALLOANTIBODIES IN SCREENING FOR RENAL-TRANSPLANTATION [J].
SUTTON, PM ;
HARMER, AH ;
BAYNE, AM ;
WELSH, KI .
TRANSPLANT INTERNATIONAL, 1995, 8 (05) :360-365
[28]   Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection [J].
Theruvath, TP ;
Saidman, SL ;
Mauiyyedi, S ;
Delmonico, FL ;
Williams, WW ;
Tolkoff-Rubin, N ;
Collins, AB ;
Colvin, RB ;
Cosimi, AB ;
Pascual, M .
TRANSPLANTATION, 2001, 72 (01) :77-83